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ABSTRACT
The goal of this studywas to investigate the association of natural killer (NK) cell recoverywith clinical outcomes
after unmanipulated haploidentical blood and marrow transplantation. We sequentially monitored the reconsti-
tution kinetics of circulating NK cells, CD56bright and CD56dim, in 43 patients by flow cytometry, and the func-
tionality recovery of cytokine or cytotoxicity of NK cells by flow cytometry or lactate dehydrogenase release
assay after transplantation. Reconstitution of NK cells was rapid but accompanied by skewing of cell subsets
mainly in CD56bright, which recovered earlier. Linear regression analysis demonstrated that dose of CD341 cells
in the allografts was inversely correlated with the ratio of T/NK cells (b 5 20.506, P 5 .003) and CD56dim/
CD56bright cell (b 5 2.403, P 5 .018) by day 14 after hematopoietic stem cell transplantation (HSCT), and
the dose of CD31 T cells in the allografts was also inversely correlated with the ratio CD56dim/CD56bright cells
by day 14 after HSCT (b520.474, P5 .005). Moreover, the dose of CD56dim NK cells in the allograft was pos-
itively associated with the day 14 CD56brigh NK cells (b5 0.494, P5 .032) and inversely correlated with the day
14 ratio of CD56dim/CD56bright cells (b520.617, P5 .005). Compared with nonacute graft-versus-host disease
(GVHD) patients, patients with acute GVHD (aGVHD) had a higher level of NK subsets during week 2 post-
transplantation. Cox regression analysis revealed that the patients withmoreCD56bright NK cells in the recovery
stage had a higher survival rate (hazard risk [HR], 0.406; P5 .017) and the patients with a higher ratio of T/NK
(.1.0) had a higher chance of getting aGVHD (HR, 3.436; P5 .059) and chronic GVHD (HR, 3.925; P5 .028).
Our results suggest that the recovery of NK cells is and can be used as an indicator to predicate the clinical
outcomes after unmanipulated haploidentical transplantation.
 2008 American Society for Blood and Marrow Transplantation
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Natural killer (NK) cells play an important role in
the innate host defenses. They specialize in killing
virus-infected cells and tumor cells by secreting gran-
zyme B similar to those of cytotoxic T lymphocytes.
There are 2 distinct subsets of human NK cells—
CD56dim and CD56bright NK cells—with distinct
functional and phenotypic properties. Approximately
90% of NK cells are CD56dim NK cells, expressing in-
termediate-affinity IL-2R and demonstrating en-
hanced cytotoxicity activity without proliferation in
response to high (nanomolar) concentrations of IL-2,whereas approximately 10% are CD56bright NK
cells, expressing high-affinity IL-2R and proliferating
in response to low (picomolar) concentrations of IL-2
[1,2]. Generally, resting CD56dim NK cells are
more cytotoxic against NK-sensitive targets than
CD56bright; however, by activation with IL-2 or IL-
12, CD56bright cells exhibit similar or enhanced cyto-
toxicity against NK targets compared to CD56dim
cells. CD56bright NK cells are identified as the execu-
tor of NK cells both in cytokine production and in
innate immunoregulatory [3]. Moreover, CD56bright
NK cells, expressing high levels of lymph node (LN)323
324 Y.-J. Chang et al.homing molecules L-selectin, CCR7 and CXCR3, are
often presented in normal human LN-enriched T cells
and dendritic cells (DCs) [4], indicating that interac-
tions between these cells occur in vivo [4,5].
NK cells are the first cells to recover after autolo-
gous or allogeneic BM or peripheral blood stem cell
(PBSC) transplantation. The effects of NK cells and
its alloreactivity on the outcomes of transplantation
are controversial in different transplant settings [6-8].
Nguyen et al [9] reported that the increased fraction
of CD56bright NK cells was associated with the impair-
ment of early reconstituted NK cytotoxicity, which ac-
counted for the high relapse rate after purified CD341
haploidentical transplantation. However, no studies
were done in the past to show the reconstitution kinet-
ics of NK cells and its contribution to clinical outcomes
after unmanipulated haploidentical transplantation,
which promotes us to monitor the orderliness of circu-
lating NK and its subsets after haploidentical blood and
marrow transplantation in our model. Our studies sug-
gested that the reconstituted CD56bright NK cells was
an early indicator for survival, and the ratio of T/NK
cells was a useful predictor for acute and chronic
GVHD (aGVHD, cGHVD) after transplantation.
MATERIALS AND METHODS
Patients
Patients with hematologic malignancies suitable
for allogeneic hematopoietic stem cell transplantation(HSCT) without HLA-identical related or unrelated
donors were candidates for the haploidentical
HSCT. Forty-three patients with malignant hemato-
logic disease, who underwent haploidentical allo-
HSCT between April 2004 and April 2005, were
included in this study. All patients and their donors
gave written informed consent, and the institutional
review board of Peking University Institute of Hema-
tology approved this study. The characteristics of the
43 patients are shown in Table 1.
Conditioning Regimen, Mobilization, Collection of
Stem Cells, and GVHD Prophylaxis
All patients received myeloablative regimens in-
cluding a combination of cytosine arabinoside (Ara-
C) (4 g/m2  2 days, on days 210 and 29), busulfan
(12 mg/kg administered orally in 12 doses over 3
days, on days 28, 27, and 26), cyclophosphamide
(1.8 g/m2  2 days, on days 25 and 24), Simustine
(MeCCNU) (250 mg/kg on day 23), and porcine an-
tihuman thymocyte immunoglobulin (Thymoglobulin
2.5mg/kg per day i.v. of the Sangstat product) on days
25 through 22 [10,11].
Donors received rhG-CSF (Filgrastim) 5 mg/kg
daily for 5 to 6 days. On the fourth day, bone marrow
cells were harvested. The target total nucleated cell
count reached 3.0  108 (median, 3.6  108, range,
0.24-8.16  108) cells/kg recipient weight. On the
5th and 6th days, peripheral blood progenitor cellsTable 1. Patients and Graft Characteristics of the Low, Middle, and High CD56bright NK Patient Group
Characteristics Overall Low CD56bright Group Middle CD56bright Group High CD56bright Group
N 43 14 15 14
Patient age, Mean ± SD 26.7 ± 13.6 27.8 ± 17 25.3 ± 8.7 26.1 ± 13.7
Donor age, Mean ± SD 41 ± 8.5 38.8 ± 9.8 44.9 ± 8.2 41.36 ± 5.8
Patent sex, male, n (%) 29(67%) 9(64%) 12(80%) 8(57%)
Diagnosis
AML, n (%) 14(33%) 4(29%) 6(40%) 4(29%)
ALL, n (%) 12(28%) 5(36%) 3(20%) 4(29%)
CML, n (%) 16(37%) 5(36%) 5(33%) 6(43%)
MDS, n (%) 1(2%) 0(0%) 1(7%) 0(0%)
High risk,* n (%) 17(40%) 8(57%) 6(40%) 3(21%)
Patient/donor HLA
compatibility
Single locus (%) 10(23%) 4(29%) 2(13%) 4(29%)
Two locus (%) 17(40%) 5(36%) 8(53%) 4(29%)
Three locus (%) 16(37%) 5(36%) 5(33%) 6(43%)
Mean ± SD
CD34 infused, 106/kg 2.6 ± 1.4 2.6 ± 1.5 2.1 ± 1.1 3.0 ± 1.4
CD3 infused, 108/kg 2.2 ± 1.4 1.9 ± 1.4 1.4 ± 0.8 2.2 ± 0.6
CD56 infused, 108/kg 0.25 ± 0.16 0.13 ± 0.01 0.24 ± 0.21 0.29 ± 0.09
CD56dim infused, 108/kg 0.21 ± 0.11 0.11 ± 0.02 0.19 ± 0.12 0.26 ± 0.09
Patients were subgrouped into ‘‘high,’’ ‘‘middle,’’ and ‘‘low’’ groups based on a 33 and 67 percentage of circulating CD56bright NK cell counts by
day 14 after transplantation.
MDS indicates myelodysplastic syndromes.
*Pretransplantation risk category included standard or high risk. Patients with standard risk were defined as those undergoing transplantation
during the first complete remission (CR1) of acute leukemia or the first chronic phase (CP1) of chronic myelogenous leukemia. Patients with
high risk were those with myelodysplastic syndrome and a more advanced stage of acute leukemia or chronic myelogenous leukemia other
than CR1/CP1.
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count reached 3.0  108 (median, 3.65  108, range,
2.77-11.7  108) cells/kg recipient weight. The fresh
and unmanipulated bone marrow and PBPCs were in-
fused into the recipients on the day of collection
[10,11].
Prophylaxis for GVHD included cyclosporine A
(CSA) and short-term methotrexate (MTX) with my-
cophenolate mofetil (MMF) [10,11]. Cyclosporine
was started intravenously on day 29, at the dosage of
2.5 mg/kg, and switched to oral formulation as soon
as the patient was able to take medication after engraft-
ment. The dosage was adjusted to blood levels. MMF
was administered orally, 0.5 g every 12 hours, from day
9 before transplantation to day 30 after transplanta-
tion, then 0.25 twice a day for 1 to 2 months. The dos-
age of MTX was 15 mg/m2, administered i.v. on day 1,
and 10 mg/m2 on days 3, 6, and 11 after transplanta-
tion. The diagnosis and grading of GVHD was estab-
lished according to published criteria [12]. Filgrastim
(granulocyte-colony stimulating factor [G-CSF]) 5
mg/kg per day was given to all recipients subcutane-
ously from day 6 after transplantation until the neutro-
phil count reached 0.5  109 cells/L for 3 consecutive
days [10,11]. Bone marrow aspiration and cytogenesis
studies were performed at 1, 2, and 3 months after
transplantation to assess engraftment. HLA DNA
typing and PCR-DNA fingerprinting (short tandem
repeat) were used for donor chimerism detection.
For each patient, at least 2 methods were used to
confirm donor chimerism.
Immunopheotypic Analysis
Blood (10 mL) was drawn from 43 patients at day
14, 21, 30, 60, 120, and 180 after transplantation,
and from 15 donors. All the samples were drawn within
4 days of the specified days. Peripheral blood (PB) lym-
phocytes were isolated using Ficoll-Hypaque density
centrifugation, and were analyzed for reactivity with
a series of mAbs using standard techniques. Monoclo-
nal antibodies (mAbs) CD16-FITC, CD56-PE were
used in combination with anti-CD45-Percp and
anti-CD3-APC (BD Bioscience, Mountain View,
CA). Individual 4-color flow cytometry assays were
used to analyze the immunophenotype recovery of
the lymphocyte including CD31 T cells, CD561
NK cells and its subsets after transplantation. Samples
were available on 43 patients at day 14, 26 patients at
day 21, 43 patients at days 30 and 60, 27 patients
at day 120, and 26 patients at day 180.
NK Cell Preparation and Cytotoxicity Assay
PB samples were collected from the donors prior
to BM harvest and PBSC collection (n 5 8) and from
patients at day 30 (n 5 11). Patient- (n 5 3) or do-
nor-derived (n 5 3) NK cells [NK cells were isolatedby depletion of T, B, and myeloid cells (Miltenyi
Biotec, Bergish Gladbach, Germany; purity $95%)]
and patient (n 5 8) or donor (n 5 5) PBMNCs were
cultured respectively in medium (RPMI with 10% fetal
calf serum, 100 U/mL penicillin, 100 U/mL strepto-
mycin, and 1% glutamine) with or without the pres-
ence of 1000 IU/mL IL-2 (Xiamen Amoytop Biotech
Co. Ltd, Fujian, China) for 16-18 hours for spontane-
ous and IL-2-stimulated (LAK) NK cytotoxicity assay.
Cytotoxicity of NK cells was examined using
major histocompatibility complex (MHC) class I-
deficient human erythroleukemia K562 cell line as tar-
gets, at effector-target ratios ranging from 20:1 to
2.5:1. Commercial cytotoxicity assays based on lactate
dehydrogenate (LDH) detection was used according
to the manufacturer’s instructions (Cytotox 96;
Promega, Madison, WI).
Interferon-g (IFN-g) Production Detected by
Intracellular Flow Cytometry
Intracellular staining was performed with the Par-
mingen Intracellular Staining kit (BD Parmingen, San
Diego, CA). Donor (n 5 5) and recipient (n 5 9)
PBMCs by day 30 (5  106/mL) were incubated with
medium alone, or 1000 IU/mL IL-2 for 16-18 hours.
Then cells were incubated for 5 hours with or without
phorbol myristate acetate (PMA) (50 ng) plus 100 ng of
inomycin (all reagents from Sigma Chemical,
St. Louis, MO) to stimulate maximal IFN-g produc-
tion. Golgistop (5 mL/mL) was added during the last
4 hours to trap the protein in the cytoplasm. The
remaining operations followed the instruction of
Parmingen Intracellular Staining kit. Monoclonal an-
tibodies CD3-percp, CD56-PE, and IFN-g-FITC
(BD Bioscience) stained for surface markers and intra-
cellular cytokines, respectively.
Statistical Analysis
Nonparametric Mann-Whitney’s U test was used
in evaluation the difference of NK cell recovery be-
tween healthy donors and patients after transplanta-
tion as well as between the patients with 0-I
aGVHD and II-IV aGVHD. Statistical associations
between pretransplantation variables and lymphocyte
recovery after transplantation were investigated using
linear regression analysis. The associations between
NK cells recovery and posttransplantation outcomes
were analyzed by the methods of Kaplan-Meier or cal-
culated using cumulative incidence curves to accom-
modate competing risks [13]. A log-rank test was
used in survival, and a Grey test was used in cumula-
tive incidence analyses. To confirm outcomes and
adjust for potential confounding factors, multivariate
Cox proportional hazards models were assessed for
the proportional hazards assumption and for testing
interaction terms with covariates. Factors included in
the models were recipient and donor ages, sex,
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egory, dose of CD31 T cell group, and dose of
CD341 cells and the absolute number of day 14
CD56bright NK cells, day 14 CD56dim NK cells, day
14 T cells, as well as the ratio of the day 14
CD56dim/CD56bright NK cells, day 14 T/NK cells.
The final multivariate models were built using a for-
ward stepwise model selection approach. Patients’
characteristics in ‘‘high,’’ ‘‘middle,’’ versus ‘‘low’’
CD56bright NK cells groups were compared using
chi-square statistics for categoric variables and
Mann-Whitney U for continuous variables, respec-
tively. The calculations were carried out with SPSS
13.0 statistical software. R software was used to calcu-




Patient characteristics including age, sex, underly-
ing hematologic disorder, the degree of HLA dispar-
ity, the amount of CD31 T cells and CD341 cells,
NK cells and its subset CD56dim, were presented in
Table 1. All the patients achieved engraftment and
complete donor chimerism after transplantation. As
of June 1, 2006, there were 29 patients who survived
without leukemia, 11 patients died of transplant-
related complications after HSCT, and 3 patients
relapsed on days 300, 180, and 44, respectively. The
median follow-up was 377 days (range: 43-700 days).
There were 18 and 25 patients who had 0-I aGVHD
and II-IV aGVHD in a series of 43 patients, respec-
tively. Among 37 patients evaluated for the cGVHD
who survived longer than 100 days, 19 patients had
occurred limited (15 patients) and extensive (4 pa-
tients) cGVHD.
Reconstitution Kinetics of Circulating NK Cells
after Unmanipulated Haploidentical Blood and
Marrow Transplantation
The quantitative evaluation of circulating NK cells
after HLA mismatched/haploidentical blood and mar-
row transplantation without in vitro T cells depletion
was performed in a series of 43 patients. For compari-
son, 15 age-matched healthy donors were used as con-
trol. Because the occurrence of aGVHD and its
therapy would affect the immune recovery, only 16
of 43 patients survived without leukemia and were ex-
empt from II-IV aGVHD; the reconstitution kinetics
of NK cells were analyzed in all 43 patients as well as
in those 16 who never developed GVHD.
Reconstitution of NK cells was rapid, but accom-
panied by skewing of cell subset, with a fast increase
in CD56bright NK subset and a corresponding reduc-
tion in CD56dim NK subset among the NK cells com-
pared with those of healthy control during first 2month after transplantation (P\ .01). Then the ratio
of CD56dim/CD56bright NK subsets in patients even-
tually reached the level similar to that of healthy con-
trol by day 120 in those 16 who never developed
GVHD (P 5 .055) (Figure 1A1), or by day 180 in all
43 patients (P5 .191; Figure 1A2). The absolute num-
ber of CD56bright NK subset in white blood cells
(WBCs) and number of CD56bright NK subset had re-
covered to the donor’s level by day 14, and continu-
ously increased up to their highest levels by day 60 in
those 16 who never developed GVHD or by 120 in
all 43 patients, which were higher compared with those
of healthy controls (P\ .05; Figure 1B1 and 1B2). In
contrast, those levels of CD56dim NK subset were
lower than the donor levels by day 14 (P \ .01;
Figure 1B1), then recovered to the donor levels by
day 30 after transplantation in those 16 who never de-
veloped GVHD. However, the absolute number of
CD56dim NK subset recovered later, which reached
to those of donor levels by day 180 after HSCT in all
43 patients (Figure 1B2). Therefore, the absolute
number of overall NK cells recovered to the donors’
levels by day 30 in those 16 who never developed
GVHD or by day 60 in all 43 patients.
It also should be noted that CD31T cells reconsti-
tuted more slowly than CD561 NK cells. Both of the
proportion in WBC and the absolute number of the
CD31 T cells in patients were significantly lower
than those levels of the donors during 1 month after
transplantation (P\ .001), then recovered to the do-
nors’ levels by day 60. Accordingly, the ratio of T/
NK cells was lower in patients by day 14 (median:
0.86, range: 0-3.55, P\ .0001) and 30 (median: 1.46,
range: 0.14-12.14, P5 .001) compared with that of do-
nors (median: 7.43, range: 3.16-15.44), and recovered
to the donors’ levels by day 60 (Figure 1C1) in those
16 who never developed GVHD. The ratio of T/NK
cells recovered to the donors’ levels by day 120 in all
43 patients (Figure 1C2).
There were 6 children (age#18years) among these
16 patients. When we assessed them separately, no dif-
ferences were found in the NK or T cell immune re-
covery between the older (age .18 years) and the
youger (age #18 years) (data not shown).
Functional Evaluation of NK Cells after
Unmanipulated Haploidentical Blood and Marrow
Transplantation
The cytotoxicity and cytokine secretion function
of NK cells were evaluated in those patients without
aGVHD and their donor. The capability of NK cells
to produce IFN-g in response to nonspecific stimula-
tion was analyzed by intracellular flow cytometry.
The ability of the patient-derived NK cells with or
without IL-2 preactivation to produce IFN-g was
similar to those of donor-derived NK cells by day
30 after transplantation. Under IL-2 activation, the
Effects of NK Cell Recovery on Transplant Outcomes 327Figure 1. Kinetics reconstitution of NK and its subsets after HLA-mismatched/haploidentical HCT without in vitro T cells depletion. Donors
(D) or donor-derived patients NK cells and its subsets, CD56bright and CD56dim NK cells, as well as T cells after transplantation (30, 60, 90, 120,
and 180 days) were monitored by cytometry. The median, 25 to 75 percentile ranges, and extreme values of the absolute numbers of NK and its
subsets (A1 and A2), or ratio of CD56dim/CD56bright NK cells (B1 and B2) and T/NK (C1 and C2) were shown in the box plot. Cells/mL indicates
the absolute number in WBC of overall NK cells and its subset. The reconstruction kinetics of the 16 patients without II-IV aGVHD were shown
in A1, B1, and C1; those of the overall 43 patients were presented in A2, B2, and C2. *Represent P\ .05 compared to their donors. **Represent
P\ .01 compared to their donors.cytokine production potential in patient- or donor-
derived NK cells was increased by 2- to 3-fold
(Figure 2A).
The cytotoxicity capability of purified patient- or
donor-derived NK cells against K562 cells was
assessed by LDH release assay. The spontaneous oractivated (IL-2 activated) killing potential of patient-
derived NK cells (either using purified NK cells or
peripheral blood mononuclear cells; Figure 2B and
C, respectively) were lower than those of the donor
derived cells by day 30 after transplantation (P\ .01;
Figure 2B and C).
328 Y.-J. Chang et al.Figure 2. The functionality recovery of cytokine and cytotoxicity of NK cells after transplantation. The capability of NK cells to produce IFN-g
in response to PMA plus inomycin stimulation was analyzed by intracellular flow cytometry. The ability of the patient-derived NK cells with (,)
or without IL-2 (-) preactivation to produce IFN-g was similar to those of donor-derived NK cells by day 30 after transplantation (A). The
cytotoxicity capability of purified patient- or donor-derived NK cells and patient- or donor-derived PBMNCs against K562 cells was assessed
by LDH release assay. The spontaneous or activated (IL-2 activated) killing potential of patient-derived NK cells or PBMNCs were lower than
those of donor-derived by day 30 after transplantation (B,C; P\ .01).Interrelationship of Day 14 NK Recovery and
Pretransplantation Variables
No correlation were found between the dose of
CD341 cell or CD31T cells in the allograft and the ab-
solute counts of NK cells at any time after transplanta-
tion. However, we found that the dose of CD341 cells
in the allograft was inversely correlated with the ratio ofT/NK cells (b 5 20.506, P 5 .003; Figure 3A) and
CD56dim/CD56bri cells (b 5 20.403, P 5 .018;
Figure 3B) by day 14 after HSCT. The dose of
CD31T cells was also inversely correlated with the ra-
tio of CD56dim/CD56bright cells by day 14 after HSCT
(b 5 20.474, P 5 .005; Figrue 3C). The dose of NK
cells in the allograft was examined in only 20 donors
Effects of NK Cell Recovery on Transplant Outcomes 329Figure 3. Interrelationship of day 14 NK recovery and doses of CD341, CD31 cells, and CD56dim NK cells in allograft. The dose of CD341 cells
in the allograft inversely correlated with the ratio of T/NK cells (A) and CD56dim/CD56bri cells (B) by day 14 after HSCT. The dose of CD31T
cells also inversely correlated with the ratio of CD56dim/CD56bright cells by day 14 after HSCT (C). The dose of CD56dim NK cells positively
associated with the absolute number of the day 14 CD56bright NK cell (E), therefore inversely correlating with the ratio of CD56dim/CD56bright
cells by day 14 after HSCT (F).and 3 in the low CD56bright group, 8 in the middle
CD56bright group, 9 in the high CD56bright group
(Table 1). The dose of CD56dim NK cells was positively
associated with the absolute number of CD56bright NK
cells on day 14 (b5 0.494, P5 .032; Figure 3D) and in-
versely correlated with the day 14 CD56dim/CD56bri
ratio (b 5 20.617, P 5 .005; Figure 3E). There was
no effect of dose of NK cells and its subsets on the
day 14 T/NK cell ratio.
Effect of aGVHD Occurrence and Its Therapy on
NK Cells Recovery after Unmanipulated
Haploidentical Blood and Marrow Transplantation
The initial appearance of clinical signs of GVHD
occurred at a median of 22.5 days posttransplantation
(range: 12 to 33 days). As early as day 14 posttransplan-
tation, significant differences in the distribution of
lymphoid subsets were observed. Patients who subse-
quently developed II-IV aGVHD tended to have
a greater proportion in WBC of CD561 NK cells
and its subsets (P 5 .060 for CD56bright subset,
Figure 4A; P 5 .012 for CD56dim subset, Figure 4B;
P 5 .036 for CD561 NK cells, Figure 4C), CD31 T
cells (P5 .001; Figrue 4D), as well as a higher absolute
numbers of CD31T cells (P5 .001; Figure 4E) by day
14 after transplantation than patients who developed
0-I aGVHD. When the ratio of T/NK was examined,
significant differences were again noted (P 5 .004;Figure 4F). Therefore, in the majority of cases, the
striking difference in lymphocytes recovery in patients
with grades 0-I and grades II-IV aGVHD was seen at
a time before any clinical signs of aGVHD were
detected.
However, when aGVHD was clinically evident
and already treated, differences could no longer be
found in the ratio of T/NK and the levels of T cells
by day 60 posttransplantation. Furthermore, patients
with II-IV aGVHD showed delayed recovery of NK
cells and its subsets proportion in WBC compared
with those with 0-I aGVHD by day 30 and/or 60
(P\ .05). No difference in the distribution of the ab-
solute number of NK cells and its subsets were ob-
served in patients with 0-I and II-IV aGVHD.
Predictive Value of CD31TCells and Ratio of T/NK
Cells on aGVHD and cGVHD
The early detection of elevated T cells, NK cells,
and T/NK ratios reconstitution in individuals who de-
veloped II-IV aGVHD led us to examine the predic-
tive value of specific phenotypic profiles. We again
focused on day 14 posttransplant, because clinical
signs had not yet appeared at this point in most pa-
tients who developed aGVHD.
Factors included in the stepwise multivariate
Cox proportional hazards model were recipient
and donor ages, sex, diagnosis, HLA mismatch,
330 Y.-J. Chang et al.Figure 4.The occurrence of aGVHD delays the recovery of the NK subset. Donors (D) or donor-derived patient NK cells and its subsets, as well
as T cells after transplantation (30, 60, 90,120, and 180 days) were monitored by cytometry. Results were presented for donors or patients sep-
arated by 0-I and II-IV aGVHD. The median, 25 to 75 percentile ranges, and extreme values of the percentages or absolute number of NK and its
subsets, as well as T cells or ratio of T/NK cells (A-F) are shown in the box plot. TNC% indicates the absolute proportion in WBC of overall NK
cells and its subset, or of T cells (A-D); cells/mL indicates the absolute number in WBC of T cells (E); black and white column represent the
groups of 0-I and II-IV GVHD, respectively. *Represents P\ .05 between patients with 0-I and II-IV aGVHD; **represents P\ .01 between
patients with 0-I and II-IV aGVHD.pretransplantation risk category, dose of CD31 T
cells, and dose of CD341 cells and the absolute num-
ber of day 14 NK cells and its subsets, day 14 T cells,
as well as the ratio of the day 14 CD56dim/CD56bright
NK cells, day 14 T/NK cells. The account of CD31T
cells (T14) and ratio of T/NK cells by day 14 after
transplantation emerged as independent factors
strongly associated with aGVHD; meanwhile, the ra-
tio of T/NK was the only significant risk factors for
cGVHD (Table 2). There was no impact of age, sex,
pretransplantation risk category, numbers of HLA-
A/B/DR loci mismatch between donor-recipients, or
dose of CD341 or CD31 T cells in the allograft and
absolute account of NK cells and its subsets by
day 14 posttransplantation (NK14, CD56bri14,
CD56dim14) on aGVHD and cGVHD. Patients were
subgrouped into ‘‘low’’ and ‘‘high’’ CD31 T cells
group or ‘‘low’’ and ‘‘high’’ T/NK ratio group accord-
ing to the optimal cutoff point of circulating T14 (34.0
cells/mL) or T/NK ratio (1.0) based on their respective
ROC curves and sensitivity/specificity curves. Patients
in the ‘‘high’’ CD31 T cells group had the higher cu-
mulative incidence of II-IV aGVHD (99.4% versus
44.4%, P 5 .001) and III-IV aGVHD (70.3% versusTable 2.Multivariate Analysis for LFS, II-IV aGVHD, and cGVHD
Outcome and Factors OR (95%CI) P-Value
LFS
CD56bri14 group 0.406(0.193-0.852) 0.017
2-4 GVHD
T14 (.34 cells/mL vs.
\34 cells/mL)
2.162(1.023-6.665) 0.045
Ratio of T/NK (.1.0 vs. #1.0) 3.436(0.954-12.378) 0.059
cGVHD
ratio of T/NK (.1.0 vs. #1.0) 3.925(1.157-13.315) 0.028
To avoid potential confounding factors, multivariate Cox propor-
tional hazards models were assessed for testing interaction terms
with covariates. Factors included in the multivariate models were
recipient and donor ages, sex, diagnosis, HLA mismatch, pre-
transplantation risk category, dose of CD31 T cells, and dose
of CD341 cells and the absolute number of day 14 NK cells
and its subsets, day 14 T cells, as well as the ratio of the day 14
CD56dim/CD56bright NK cells, and day 14 T/NK cells. The final
multivariate models were built using a forward stepwise model
selection approach. Patients were subgrouped into a ‘‘high,’’
‘‘middle,’’ and ‘‘low’’ group based on a 33 and 67 percentage of
circulating CD56bright NK cell count by day 14 after transplanta-
tion (CD56bri14 group). Cutoff points of day 14 T cell count
(T14) or day 14 ratio of T/NK was 34 cells/mL or 1.0 by day
14 after transplantation.
OR indicates odds ratio; CI, confidence interval; LFS, .
Effects of NK Cell Recovery on Transplant Outcomes 33110.5%, P 5 .003) compared with those in the ‘‘low’’
CD31 T cells group.
The ratio of T/NK cells was also a significantly in-
dependent positive predicator for cGVHD (HR, 3.925,
95% confidence interval [CI], 1.157-13.315, P5 .028,
Table 2). As showed in Figure 5A, B, and C, cumulative
incidence curves for II-IV, III-IV aGVHD, and
cGVHD were shown with a ‘‘low’’ (#1.0, n5 14) ver-
sus ‘‘high’’ (.1.0, n5 29) ratio of T/NK cells. Patients
in the ‘‘high’’ ratio of the T/NK cells group had the
higher cumulative incidence of II-IV aGVHD
(82.4% versus 23.8%, P 5 .002; Figure 5A) and III-
IV aGVHD (73.1% versus 7.1%, P 5 .017;
Figure 5B) compared with those in the ‘‘low’’ ratio of
the T/NK cell group. Because 6 patients died before
day 100, only 37 of 43 patients enrolled in the analysis
of the relationship between the ratio of T/NK cells and
the occurrence of cGVHD after transplantation. The
cumulative incidence of cGVHD in patients with
a ‘‘high’’ T/NK ratio were significantly higher than
those patients with a ‘‘low’’ T/NK ratio (73.1% versus
28.4%, P5 .013; Figure 5C). However, no differences
in the occurrence of cGVHD were found between the
patients in the ‘‘high’’ and ‘‘low’’ (64.7% versus 55.4%,
P5 .554) CD31 T cells groups.
Predictive Value of Early Posttransplantation
CD56bright NK Cells Count on Survival
Using the same Cox model, the only independent
variable affecting the overall survival (OS) was the
number of the day 14 CD56bright NK cell (HR,
0.406, 95% CI, 0.193-0.852, P 5 .017; Table 2). To
assess the possibility of using the number of CD56bright
NKcells as apositive predictor for LFS,patients werecat-
egorized into the ‘‘low’’ group (\3.59 cells/mL, n5 14),
‘‘middle’’ group (3.59 to 9.27 cells/mL, n 5 15), and
‘‘high’’ group (.9.27 cells/mL, n 5 14), based on33% and 67% percentage of circulating CD56bright
NK cell count. As showed in Table 1, there were no sig-
nificant difference in the patients’ characteristics in-
cluding age, sex, diagnosis, pretransplantation risk
category, the degree of HLA disparity, and the dose
of CD31T cells, CD341 cells, NK cells and its subsets
in the grafts among the 3 groups. A highest 2-year cu-
mulative incidence of OS was observed in patients of
the ‘‘high’’ CD56bright NK cells group (92.9% versus
42.9% of the ‘‘low’’ group, P 5 .006), followed by pa-
tients in the ‘‘middle’’ (66.7% versus 92.9%, P 5 .064)
and ‘‘low’’ CD56bright NK cell group (42.9%)
(Figure 6A). Furthermore, Kaplan-Meier univariate
analysis showed the patients with rapid recovery of
CD56bright NK cells seemed to be associated with
less transplantation-related mortality (TRM) and re-
lapse. The cumulative incidence of TRM and relapse
in patient of the ‘‘high’’ group tended to be lower than
those of the ‘‘low’’ group (7.1% versus 44.4% of
TRM, P 5 .025; Figure 6B, and 0% versus 20.5% of
relapse, P5 .090, respectively).
DISCUSSION
In the current study, we investigated the reconsti-
tution kinetics of peripheral NK cells after HLA-mis-
matched/haploidentical HCT without in vitro T cells
depletion and found that CD56bright subset domi-
nanted in the early stage, and this prolonged increasing
of CD56bright NK cells could be associated with im-
pairment of NK cytotoxicity during the early recovery
of NK cells. This result is consistent with the study in
unmodified HLA-identical or purified CD341 cells
HLA-haploidentical HCT [9,14,15]. Furthermore,
the early rapid recovery of circulating CD56bright
NK cells was correlated with better survival; ‘‘high’’ ra-
tio of T/NK (.1.0) was an independent predictor forFigure 5. The high ratio of T/NK cells correlated with the increased occurrence of aGVHD and cGVHD after HSCT. Patients were sub-
grouped into the ‘‘low ratio of T/NK cells (#1.0)’’ and the ‘‘high ratio of T/NK cells (.1.0)’’ groups based on less or more than the ratio of
1.0, and subgrouped into the ‘‘low’’ and ‘‘high’’ CD31 T cells group according to the median circulating CD31 T cells counts of 31.36 cells/
mL by day 14 after transplantation. Cumulative incidence estimates of II-IV aGVHD (A), III-IV aGVHD (B), and cGVHD (C) in these 2
and 4 cohorts, respectively.
332 Y.-J. Chang et al.Figure 6. The high number of circulating CD56bright NK cells correlated with better OS and less TRM. Patients were subgrouped into the
‘‘high,’’ ‘‘middle,’’ and ‘‘low’’ group based on the 33 and 67 percentage of circulating CD56bright NK cell count by day 14 after transplantation.
Kaplan-Meier survival estimates OS (A) in these 3 groups and cumulative incidence estimates TRM (B).posttransplantation aGVHD and cGVHD in this
transplantation protocol.
Compared with result demonstrated by Nguyen et
al [9], which showed that 7 out of 10 relapsed and 3 out
of 10 died, the clinical outcomes of our study were en-
couraging; only 3 patients out of a total of 43 relapsed
and 11 died of transplantation-related complication af-
ter haploidentical transplant without in vitro T cells
depletion. In our transplantation model the number
of NK cells and its subsets’ reconstitution kinetics
are similar to that of the Nguyen et al report. In Nguy-
en’s study, CD31 T cells reconstituted slowly and
could not be detected until the fourth month after pu-
rified CD341 haploidentical transplantation. The loss
of T cells results in the deficiency of T cell antitumor
function. The rapid reconstituted NK cells may play
an antitumor role in the early stage after purified
CD341HSCT. The number of CD31T cells reached
that of the donor’s level 2 months after transplantation
in our model. Both numbers of CD56dim and
CD56bright NK reached the number of those in do-
nor’s body 1 month after transplantation. The rapid
recovery of NK and T cells after HSCT may enable
the interaction between the NK and T cells, which
may enhance the individual antitumor and anti-infec-
tion effect of reconstituted NK and T cells after trans-
plantation. Previous studies have demonstrated that
the CD56bright NK cells are enriched in the T cell re-
gion of resting LNs [4,5], and the communication
among CD56bright NK cells, DC cells, and T cells is
crucial for the interaction between adaptive and innate
immunity [4,5]. As far as the cytotoxicity of NK cells is
concerned, we found that the spontaneous or activated
(IL-2 activated) killing potential of patient-derived
NK cells by day 30 after transplantation were lower
than those of the donor-derived cells. In vitro experi-
ments demonstrated that NK cell cytotoxicity could
be retained or decreased after being treated with
CSA or MTX [16,17]. Therefore, the effects of CSA
and MTX on this altered cytotoxicity could not be ex-cluded completely and should be clarified in vivo, par-
ticularly in our transplant settings.
In this paper, we emphasized the importance of the
early rapid recovery of CD56bright NK cells. For the
first time, we showed that the early rapid recovery of
CD56bright NK cells was a good predictive sign for bet-
ter survival and less occurrence of TRM after this
HLA-mismatched/haploidentical HSCT without in
vitro T cells depletion. Although it was originally sug-
gested that CD56bright NK cells represent the precur-
sors of the CD56dim subpopulation, and the
disproportion of CD56bright and CD56dim NK cells af-
ter transplantation implies an immature NK pheno-
type [9,14,15,18]. Recent cumulative data indicated
that CD56bright and CD56dim NK cells are phenotyp-
ically, functionally, and developmentally different
from NK cell subsets. Cooper et al [3] provided evi-
dence to support the idea that CD56bright NK cells
are the major cytokine-producing subset of human
NK cells with unique immunoregulatory roles in
vivo. Therefore, the rapid expansion of donor-derived
CD56bright NK cells may have particular implication
for the immune recovery owing to their immunoregu-
lator roles and the ability to proliferate and IFN-g pro-
duction upon interaction with DC and T cells.
Although the rapid recovery of T and NK cells
could benefit from antitumor or anti-infection, we
also noticed that the rapidly recovered T cells could
became a risk factor for aGVHD after transplantation.
Furthermore, the ‘‘high’’ ratio of T/NK cells (.1.0)
increased the incidence of aGVHD. It is similar to
Soiffer’s report [19] that patients with high counts of
CD81 T cells or low counts of CD561 NK cells dur-
ing week 2 post-BMT developed high risk for aGVHD
occurrence, and none of patients with low levels of
CD81 cells and high levels of CD561 cells developed
grades II-IV GVHD after CD6-depleted allogeneic
bone marrow transplantation. Previous studies sug-
gested that NK cells in the allograft are associated
with less aGVHD occurrence after transplantation
Effects of NK Cell Recovery on Transplant Outcomes 333[20-22]; therefore, the roles of reconstituted NK cells
or its interaction with T cells in aGVHD still need to
be further explored.
To test the possibility that the ratio of early recon-
stituted T and NK cells may be more significant in
predicating the occurrence of cGVHD, we also evalu-
ated the stratified ratio of T/NK cells on the incidence
of cGVHD, and our result confirmed that the ‘‘high’’
ratio of T/NK cells (.1.0) was an independent risk
factor for the high incidence of cGVHD, whereas
the high number of CD31 T cells had no direct corre-
lation. Chronic GVHD pathogenesis may be involved
in autoreactive T cells that escape negative selection in
the thymus, which is damaged by preconditioning or
aGVHD. Th2 immune response of donor CD41 T
cells released from negative selection facilitate host B
cells to synthesize autoantibodies [23,24]. A previous
report illustrated that NK cells could generate the sup-
pressive effect of CD81 T cells on autoantibody syn-
thesis of B cells through producing transforming
growth factor-b (TGF-b) after optimal interaction be-
tween the NK and CD81 T cells [25]. Therefore, the
relative low number of NK cells over T cells (T/NK
.1.0) cannot optimally develop a suppressive effect
on T cell-mediated autoantibody synthesis of B cells.
Abrahamsen et al [26] demonstrated that patients
with extensive cGVHD showed low NK cell counts,
which suggest that a low number of NK cell counts
might be a possible pathogenesis of cGVHD.
In conclusion, our results show that although a pro-
longed high proportional CD56bright NK subset could
be associated with the impairment of NK cytotoxity af-
ter transplantation, patients with a ‘‘high’’ number of
CD56bright NK cells have an encouraging OS after
haploidentical HSCT without ex vivo T cells deple-
tion, which may be because of its potential immuno-
regulatory roles and its ability to interaction with
DC, monocyte, and T cells. Furthermore, the ratio
of T/NK cells may be involved in initiating and pre-
vention of GVHD. Therefore, further investigation
on the interaction between the immune cells (NK,
DC, and T cells) may help decrease the occurrence
of GVHD, TRM, relapse, and increase overall survival
rate.
ACKNOWLEDGMENTS
We would like to acknowledge the staff of the Pe-
king University Institute of Hematology for their help
in organizing and facilitating the collection of patient
samples and thank San Francisco Edit (www.sefedit.
net) for their assistance in editing this manuscript.
This work was supported by the National Outstanding
Young Scientist’s Foundation of China (Grant No.
30725038), Hi-tech Research and Development Pro-
gram of China (No. 2006AA02Z4A0), and Program
for Innovative Research Team in University
(IRT0702). Ying-Jun Chang performed research,analysis, and interpretation of data, drafting the article,
and final approval of the version to be published;
Xiang-Yu Zhao performed research, analysis and
interpretation of data, drafting the article, and final
approval of the version to be published; Xiao-Jun
Huang was responsible for conception and design,
revising the article critically, and final approval of the
version to be published. The authors reported no
potential conflicts of interest.
REFERENCES
1. Cooper MA, Fehniger T, Caligiuri M. The biology of human
natural killer-cell subsets. Trends Immunol. 2001;22:633-640.
2. Baume DM, Robertson MJ, Levine H, Manley TJ, Schow PW,
Ritz J. Differential responses to interleukin 2 define functionally
distinct subsets of human natural killer cells. Eur J Immunol.
1992;22:1-6.
3. Cooper MA, Fehniger TA, Turner SC, et al. Human natural
killer cells: a unique innate immunoregulatory role for the
CD56bright subset. Blood. 2001;97:3146-3151.
4. Fehniger TA, Cooper MA, Nuovo GJ, et al. CD56bright natural
killer cells are present in human lymph nodes and are activated
by T cell-derived IL-2: a potential new link between adaptive
and innate immunity. Blood. 2003;101:3052-3057.
5. Massimo Vitale MDC, Simona Carlomagno, Chiara Romagnani,
Andreas Thiel, Lorenzo Moretta, Alessandro Moretta. The small
subset of CD56brightCD162 natural killer cells is selectively re-
sponsible for both cell proliferation and interferon-r production
upon interaction with dendritic cells. Eur J Immunol. 2004;34:
1715-1722.
6. Kim DH, Sohn SK, Lee NY, et al. Transplantation with higher
dose of natural killer cells associated with better outcomes in
terms of non-relapse mortality and infectious events after alloge-
neic peripheral blood stem cell transplantation from HLA-
matched sibling donors. Eur J Haematol. 2005;75:299-308.
7. Larghero J, Rocha V, Porcher R, et al. Association of bone mar-
row natural killer cell dose with neutrophil recovery and chronic
graft-versus-host disease after HLA identical sibling bone mar-
row transplants. Br J Haematol. 2007;138:101-109.
8. Zhao XY, Huang XJ, Liu KY, Xu LP, Liu DH. Prognosis after
unmanipulated HLA-haploidentical blood and marrow trans-
plantation is correlated to the numbers of KIR ligands in recip-
ients. Eur J Haematol. 2007;78:338-346.
9. Nguyen S, Dhedin N, Vernant J-P, et al. NK-cell reconstitution
after haploidentical hematopoietic stem-cell transplantations:
immaturity of NK cells and inhibitory effect of NKG2A override
GvL effect. Blood. 2005;105:4135-4142.
10. Lu D-P, Dong L, Wu T, et al. Conditioning including antithy-
mocyte globulin followed by unmanipulated HLA-mismatched/
haploidentical blood and marrow transplantation can achieve
comparable outcomes with HLA-identical sibling transplanta-
tion. Blood. 2006;107:3065-3073.
11. Huang X-J, Han W, Xu L-P, Chen Y-H, Liu D-H, Lu J. A novel
approach to human leukocyte antigen-mismatched transplanta-
tion in patients with malignant hematological disease. Chin Med
J. 2004;117:1778-1785.
12. Glucksberg H, Storb R, Fefer Aea. Clinical manifestations of
graft-versus-host disease in human recipients of marrow from
HLA-matched sibling donors. Transplantation. 1974;18. 295-230.
334 Y.-J. Chang et al.13. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of
failure probabilities in the presence of competing risks: new rep-
resentations of old estimators. Stat Med. 1999;18:695-706.
14. Shilling HG, McQueen KL, Cheng NW, Shizuru JA,
Negrin RS, Parham P. Reconstitution of NK cell receptor rep-
ertoire following HLA-matched hematopoietic cell transplanta-
tion. Blood. 2003;101:3730-3740.
15. Chklocskaia E, Nowbakht P, Nissen C, Gratwohl A, Bargetzi M,
Wodnar-Filipowicz A. Reconstitution of dendritic and natural
killer-cell subsets after allogeneic stem cell transplantation:
effects of endogenous flt3-ligand. Blood. 2004;103:3860-3868.
16. Nakarai T, Ueno Y, Ueno Y, Koizumi S. Paradoxical enhance-
ment of interleukin-2-mediated cytotoxicity against K562 cells
by addition of a low dose of methotrexate. Cancer Immunol
Immunother. 1990;32:8-12.
17. Wang H, Grzywacz B, Sukovich D, et al. The unexpected effect
of cyclosporin A on CD561CD16- and CD561CD161 natural
killer cell subpopulations. Blood. 2007;110:1530-1539.
18. Nagler A, Lanier L, Cwirla S, Phillips J-H. Comparative studies
of human FcRIII-positive ans negative natural killer cells.
J Immunol. 1989;143:3183-3191.
19. Soiffer R, Gonin R, Murray C, et al. Prediction of graft-versus-
host disease by phenotypic analysis of early immune reconstitution
after CD6-depleted allogeneic bone marrow transplantation.
Blood. 1993;82:2216-2223.20. Asai O, Longo D, Tian Zea. Surpression of graft-versus-host
disease and amplification of graft-versus-tumor effect by acti-
vated natural killer cells after allogeneic bone marrow transplan-
tation. J Clin Invest. 1998;101:1835-1842.
21. Ruggeri L, Capanni M, Casucci M, Volpi I, Tosti A, Perruccio
Kea. Role of natural killer cell alloreactivity in HLA-mis-
matched hematopoietic stem cell transplantation. Blood. 1999;
94:333-339.
22. Yamasaki S, Henzan J, Ohno Y, et al. Influence of transplanted
dose of CD561 cells on development of graft-versus-host dis-
ease in patients receiving G-CSF-mobilized peripheral blood
progenitor cells from HLA-identical sibling donors. Bone Mar-
row Transplant. 2003;32:505-510.
23. Weinberg K, Blazar B, Wagner J, et al. Factors affecting thymic
function after allogeneic hematopoietic stem cell transplanta-
tion. Blood. 2001;97:1458-1466.
24. Iwasaki T. Recent advances in the treatment of graft-versus-host
disease. Clin Med Res. 2004;2:243-252.
25. Gray J-D, Hirokawa M, Horwitz D-A. The role of transforming
growth factor b in the generation of suppression: an interaction
between CD81T and NK cells. JExpMed. 1994;180:1937-1942.
26. Abrahamsen I, Sømme S, Heldal D, Egeland T, Kvale D,
Jjønnfjord G. Immune reconstitution after allogeneic stem cell
transplantation: the impact of stem cell source and graft-ver-
sus-host disease. Haematologica. 2005;90:86-93.
